STOCK TITAN

Verastem Stock Price, News & Analysis

VSTM NASDAQ

Company Description

Company Overview

Verastem (NASDAQ: VSTM) is a specialized biopharmaceutical company dedicated to the discovery and development of novel anticancer agents. With a strong emphasis on oncology and cancer research, the company targets cancer stem cells – a critical factor in tumor recurrence and metastasis. Its innovative approach focuses on interrupting key signaling pathways, such as RAF/MEK and FAK, that are crucial for cancer cell survival and tumor growth. By directly addressing these oncogenic mechanisms, Verastem aims to contribute to the development of therapies that offer a fundamental shift in cancer treatment strategies.

Scientific Focus and Research Strategy

At the core of Verastem's mission is the pioneering research into cancer stem cells. These cells are believed to be a root cause of cancer resilience and relapse, making them an essential target for effective treatment options. The company leverages breakthrough discoveries in molecular oncology to design molecules that interfere with critical cell signaling pathways. Its research not only focuses on inhibiting pathways like RAF/MEK but also explores FAK inhibition, emphasizing a multi-targeted approach to disrupt tumor-promoting mechanisms.

Pipeline and Drug Development

Verastem operates in the late stages of drug development where clinical translational research is pivotal. The pipeline encompasses investigational therapies intended to halt or reverse cancer progression by addressing the cellular mechanisms underlying tumor survival and metastasis. The company employs a rigorous drug development approach characterized by intensive scientific research, strategic clinical trials, and methodical evaluation of candidate compounds. This method ensures that its pipeline remains deeply rooted in scientific innovation and is reflective of its commitment to precision oncology.

Market Position and Business Model

Within the competitive biopharmaceutical landscape, Verastem strategically differentiates itself by focusing on the niche area of cancer stem cell biology. The company builds its business model on a foundation of high-level scientific research and translational medicine, aiming to generate substantial clinical insights that could potentially transform standard cancer care practices. Its approach is built on collaborative research and partnerships that support development and eventual commercialization, all while maintaining a rigorous commitment to scientific excellence.

Innovation in Oncology

Verastem remains committed to advancing the boundaries of oncological research. It harnesses detailed scientific methodologies and emerging technologies to explore the molecular intricacies of cancer biology. The company's focus on key oncogenic signaling pathways demonstrates its dedication to targeted therapy development, a crucial aspect of modern oncology. Through its innovative drug candidates, Verastem contributes to a broader scientific discourse by advancing novel therapeutic options and enhancing our understanding of cancer pathophysiology.

Industry Relevance and Competitive Landscape

Operating within the highly competitive field of cancer drug development, Verastem is part of an industry that demands precision and innovation. By honing in on cancer stem cells, a less conventional but highly strategic target, it distinguishes itself among traditional oncology companies. The company's research-driven approach is complemented by its ability to adapt to complex regulatory environments, making it a pertinent subject for investors and industry observers interested in transformative cancer therapy research.

Commitment to Expertise and Validation

Verastem’s initiatives are underpinned by a deep commitment to scientific research and rigorous testing, adhering to high standards of experimental design and clinical evaluation. Its work is characterized by an integrated approach that combines laboratory discoveries with clinical insights, thereby reinforcing its standing as a knowledgeable participant in the field of oncology. Through robust research protocols and continuous peer validation, Verastem exemplifies the principles of expertise, experience, authoritativeness, and trustworthiness that define its contributions to modern cancer treatment.

Stock Performance

$—
0.00%
0.00
Last updated:
-37.71 %
Performance 1 year
$255.4M
Market Cap
51.5M
Shares outstanding

SEC Filings

No SEC filings available for Verastem.

Financial Highlights

$10,000,000
Revenue (TTM)
-$130,637,000
Net Income (TTM)
-$3.66
Diluted EPS (TTM)
-$104,771,000
Operating Cash Flow
-1,306.37%
Net Profit Margin
-1,149.56%
Oper. Profit Margin

Frequently Asked Questions

What is the current stock price of Verastem (VSTM)?

The current stock price of Verastem (VSTM) is $7.5 as of April 24, 2025.

What is the market cap of Verastem (VSTM)?

The market cap of Verastem (VSTM) is approximately 255.4M.

What is the revenue (TTM) of Verastem (VSTM) stock?

The trailing twelve months (TTM) revenue of Verastem (VSTM) is $10,000,000.

What is the net income of Verastem (VSTM)?

The trailing twelve months (TTM) net income of Verastem (VSTM) is -$130,637,000.

What is the earnings per share (EPS) of Verastem (VSTM)?

The diluted earnings per share (EPS) of Verastem (VSTM) is -$3.66 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Verastem (VSTM)?

The operating cash flow of Verastem (VSTM) is -$104,771,000.

What is the profit margin of Verastem (VSTM)?

The net profit margin of Verastem (VSTM) is -1,306.37%.

What is the operating margin of Verastem (VSTM)?

The operating profit margin of Verastem (VSTM) is -1,149.56%.

What is the current ratio of Verastem (VSTM)?

The current ratio of Verastem (VSTM) is 3.07, indicating the company's ability to pay short-term obligations.

What is the operating income of Verastem (VSTM)?

The operating income of Verastem (VSTM) is -$114,956,000.

What is Verastem's primary focus?

Verastem concentrates on discovering and developing novel anticancer agents that target cancer stem cells, which are critical to tumor recurrence and metastasis. Its research focuses on disrupting key cell signaling pathways involved in cancer growth.

How does Verastem differentiate itself in the oncology sector?

Verastem differentiates itself by focusing on cancer stem cells rather than conventional tumor cells. Its research into key pathways such as RAF/MEK and FAK inhibition positions it uniquely in the competitive biopharmaceutical landscape.

What is the significance of targeting cancer stem cells?

Cancer stem cells play a crucial role in tumor relapse and resistance to conventional therapies. By targeting these cells, Verastem aims to prevent recurrence and reduce metastasis, providing a potentially more effective approach to cancer treatment.

How does Verastem generate revenue?

As a late-stage development company, Verastem’s revenue generation primarily stems from its research collaborations, licensing partnerships, and the potential commercialization of its therapeutic candidates pending successful clinical evaluations.

What are the key therapeutic areas explored by Verastem?

Verastem primarily focuses on the development of therapies that inhibit critical signaling pathways in cancer, including the RAF/MEK and FAK pathways. These areas are pivotal in the survival and growth of cancer cells.

How does Verastem's research approach contribute to the field of oncology?

The company’s research approach, which integrates laboratory discoveries with clinical insights, ensures that its drug development is both scientifically rigorous and clinically relevant. This strategy helps advance the understanding of cancer biology and informs the development of targeted therapies.